Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Amphetamine Cocaine Interaction Study - 2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00000305
Recruitment Status : Terminated (Original P.I. left the institution)
First Posted : September 21, 1999
Last Update Posted : May 18, 2012
Sponsor:
Collaborators:
National Institute on Drug Abuse (NIDA)
University of Texas
Information provided by (Responsible Party):
The University of Texas Health Science Center, Houston

Tracking Information
First Submitted Date  ICMJE September 20, 1999
First Posted Date  ICMJE September 21, 1999
Last Update Posted Date May 18, 2012
Study Start Date  ICMJE Not Provided
Primary Completion Date Not Provided
Current Primary Outcome Measures  ICMJE Not Provided
Original Primary Outcome Measures  ICMJE
 (submitted: June 23, 2005)
  • Mood indicators
  • Psychiatric interview
  • Craving
  • Drug use
  • Medication compliance
  • Retention
  • Addiction severity
Change History Complete list of historical versions of study NCT00000305 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Amphetamine Cocaine Interaction Study - 2
Official Title  ICMJE Amphetamine Cocaine Interaction Study
Brief Summary The purpose of this study is to evaluate results of d-amphetamine - cocaine (pharmacology) interaction study.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Primary Purpose: Treatment
Condition  ICMJE Cocaine-Related Disorders
Intervention  ICMJE Drug: Dextroamphetamine
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Enrollment  ICMJE
 (submitted: June 23, 2005)
0
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE Not Provided
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE Please contact site for information.
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years to 45 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00000305
Other Study ID Numbers  ICMJE NIDA-09262-2
P50DA009262 ( U.S. NIH Grant/Contract )
P50-09262-2
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party The University of Texas Health Science Center, Houston
Study Sponsor  ICMJE The University of Texas Health Science Center, Houston
Collaborators  ICMJE
  • National Institute on Drug Abuse (NIDA)
  • University of Texas
Investigators  ICMJE
Principal Investigator: John Grabowski, Ph.D. University of Texas
PRS Account The University of Texas Health Science Center, Houston
Verification Date May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP